- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
OKRA.ai Extends Collaboration with Bristol Myers Squibb
OKRA.ai, a provider of Artificial Intelligence (AI) driven analytics for global life sciences, today announced that it is extending its collaboration with Bristol Myers Squibb to leverage OKRA’s AI Technology to support future customer engagement. This collaboration, which started in the UK in 2018 has proven to be very successful in bringing together multiple data sources and generating intelligent insights for commercial teams whilst delivering unparalleled levels of automation for the company. In 2021 OKRA.ai and Bristol Myers Squibb expanded use of the system to new markets and will continue to work together and explore further expansion opportunities in 2022.
Read more about the collaboration here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
